Introduction
The intrinsic control of renal hemodynamics depends on the tubuloglomerular feedback (TGF) mechanism as well as on the myogenic mechanism (1). The former alters nephron blood flow and glomerular filtration by changing afferent arteriolar resistance in response to the sodium chloride concentration at the macula densa (2) . The TGF mechanism plays an important role in the regulation of water, electrolytes and blood pressure. In young spontaneously hypertensive rats (SHR), TGF activity is augmented compared to that in age-matched Wistar Kyoto rats, suggesting that it may participate in the initiation and/or nephrotic patients (9) via mechanisms that involve preservation of the charge barrier of the glomerulus (6) (7) (8) and reduction in GFR (6, 9) . Dipyridamole has been shown to decrease GFR in dogs (10) and humans (9, 11) . This decrease in GFR, which in humans was accompanied by a fall in filtration fraction (FF) (9) , seems to indicate a reduction in intraglomerular pressure via the vasodilatation of postglomerular efferent arterioles. While several reports have documented the renal hemodynamic effects of dilazep (6, 12, 13) , the effects in renal microcirculation have not been investigated. Because these adenosine potentiators have the potential to influence the TGF mechanism, and thereby the regulation of water, electrolytes and blood pressure homeostasis, the present experiments were undertaken to evaluate the effects of dilazep on glomerular microcirculation and the TGF mechanism in anesthetized rats.
Materials and Methods

Animal Preparations
This study was performed in accordance with the Guide for Animal Experimentation of the Shimane Medical University. Experiments were carried out on male Sprague-Dawley rats maintained on a commercial chow diet. Rats were prepared as previously described (3, 14) under anesthesia induced with 110 mg/kg i.p. thiopental sodium (Ravonal; Tanabe, Tokyo, Japan). The rat was placed on a thermostatically controlled heated table to maintain rectal temperature at 37.5˚C. A tracheostomy tube was inserted, and a PE-50 polyethylene tube (Clay Adams, Parsippany, USA) was placed in the external jugular vein for infusion of 10% polyfructosan (Inutest; Fresenius Kabi, Linz, Austria) in 0.9% saline at a rate of 4.5 ml/kg/h. The right femoral artery was cannulated with a PE-50 tube for monitoring arterial pressure and collecting blood samples. The left kidney was placed in a plastic cup, immobilized in agar, and its pelvis cannulated with a PE-10 tube to collect urine samples. A 25-gauge needle connected to a PE-50 tube was inserted into the left renal vein to collect renal venous blood. Clearance and micropuncture experiments were started 1 h after the preparation had been finished.
Whole Kidney Clearance Study
Two 30-min clearances were performed as a control period. Dilazep was then infused for three 30-min clearances. Two additional 30-min recovery clearances were performed by reinfusing saline vehicle instead of dilazep solution. Dilazep dissolved in 0.9% saline containing 10% polyfructosan was infused via the jugular vein at a rate of 0.1 mg/kg/h following the initial bolus dose of 0.1 mg/kg (low dose, n 5 rats) or 0.3 mg/kg/h following the initial bolus dose of 0.3 mg/kg (high dose, n 6 rats). Repeated blood samples were taken from the femoral artery and renal vein at the midpoint of each clearance period. The volume, approximately 600 µl per rat throughout all the experimental periods, was replaced by 0.9% saline.
Measurement of Early Proximal Flow Rate (EPFR) during Loop Perfusion
During the clearance study, TGF response was estimated by measuring the changes in EPFR, an index of single nephron GFR, while the loop of Henle was perfused from the end proximal segment with artificial tubular fluid (ATF) at a rate of 40 nl/min, as previously described (3, 14) . Successive, 3-min collections of tubular fluid were made from the early proximal segment during microperfusion at 0 or 40 nl/min. Tubular fluid was collected spontaneously, proximal to a mobile, 4-to 5-tubular diameter block of Sudan Blackstained mineral oil in 10-to 12-µm pipettes. The volume of tubule fluid was determined in a constant bore-capillary (Microcaps 1.0 µl; Drummond, Broomall, USA). The feedback response was expressed as the change in EPFR when the loop perfusion rate was increased from 0 to 40 nl/min.
EPFR measurements were performed during both the control period and the experimental period of high-dose dilazep infusion. In another group of rats (n 10), EPFR was measured during the microinfusion of a pharmacological concentration of dilazep (10 6 -10 4 mol/l) and/or an A2 selective adenosine receptor antagonist, 3,7-dimetyl-1-propargylxanthine (DMPX, RBI, Natic, USA, 10 5 mol/l) (15), dissolved in ATF.
Analytical Techniques and Calculations
The polyfructosan concentrations in plasma and urine were measured by the anthrone method. Plasma and urine sodium and potassium concentrations were measured by a flame photometer (Model 775; Hitachi, Tokyo, Japan). GFR was determined from polyfructosan clearance. Renal plasma flow (RPF) was calculated as GFR Ap/(Ap Vp), where Ap and Vp are the arterial and renal venous concentrations of polyfructosan, renal blood flow (RBF) as RPF/(1 hematocrit), and renal vascular resistance (RVR) as mean blood pressure (BP)/RBF. Results are expressed as the mean SEM. Student's paired or unpaired t-test, or analysis of variance (ANOVA) was used for comparison. When ANOVA revealed a significant difference, Fisher's protected least significant difference test was applied to identify specific group differences. Values of p 0.05 were considered to indicate statistical significance.
Results
Whole Kidney Clearance
Low-dose dilazep infusion (0.1 mg/kg 0.1 mg/kg/h) did not influence any of the clearance parameters, including systemic BP (Table 1) . However, high-dose dilazep infusion (0.3 mg/kg 0.3 mg/kg/h) clearly affected both systemic BP and renal hemodynamics (Table 2) . High-dose dilazep infusion lowered systemic BP by 5.3 2.3 mmHg. GFR was significantly decreased and RPF was unaltered; as a result, FF tended to decrease during the experiment period ( p 0.076). These parameters showed a tendency to return to the control level after the cessation of dilazep infusion, except that urine volume remained significantly low during the recovery period. The reduction in RVR during the experiment period was not significant. Urinary excretion of potassium (UKV) decreased after the cessation of dilazep infusion. Figure 1 shows the EPFR measurements in the absence of distal flow and during loop perfusion at 40 nl/min. Loop perfusion significantly decreased EPFR from 29.9 1.4 to 16.1 1.2 nl/min during the control periods (n 15), and from 29.2 1.4 to 16.6 1.9 nl/min during the experimental periods (n 9). The reductions in EPFR by loop perfusion were not different between two periods, 46.9 2.1% and 43.7 4.9% of EPFR at no loop flow, respectively. of dilazep used in this study, 10 4 mol/l, was significantly smaller than that in the controls (46.9 2.1%). The reduction by 10 4 mol/l dilazep was clearly reversed by co-perfusion of 10 5 mol/l DMPX with 10 4 mol/l dilazep into the loop of Henle; EPFR was reduced from 28.4 1.2 nl/min to 15.6 1.2 nl/min (45.4 3.1%) (n 11). Perfusion of 10 5 mol/l DMPX alone in ATF reduced EPFR from 26.0 1.4 nl/min to 14.6 1.1 nl/min (43.9 2.3%) (n 14). These reductions observed with dilazep and DMPX or DMPX alone were not significantly different from those in the control group. Figure  3 summarizes EPFR reductions during systemic infusion of dilazep and intratubular perfusion of dilazep and/or DMPX.
EPFR Response to Loop Perfusion
Discussion
In the present clearance studies, infusion of high-dose dilazep clearly decreased GFR and, because RPF did not increase significantly, FF tended to be low during the infusion. In glomerular microcirculation, such hemodynamic changes are caused by a decrease in the resistance of postglomerular efferent arterioles and/or the ultrafiltration coefficient of glomerulus (Kf). Insignificant decrease in RVR in the present study would appear to support the former mechanism. The hypotensive effect was significant but mild, and thus systemic BP remained above the lower range of renal perfusion pressure in renal autoregulation. These effects were clearly dependent on the dose of dilazep, since that low-dose dilazep infusion did not affect systemic BP or any of the other hemodynamic parameters.
To our knowledge, there have been only three reports documenting the effects of dilazep on whole-kidney function (6, 12, 13) . In one of these studies, oral administration of dilazep decreased GFR and urinary albumin excretion in nephrotic rats (6) . In another, intravenous infusion of dilazep did not change RBF in dogs, but did increase coronary blood flow and decrease systemic BP (12) . However, when dilazep was infused directly into the renal arteries of dogs in order to minimize its systemic influences, RBF was increased, RVR was decreased, and GFR remained unaltered (13) . These findings support the idea that renal vasodilatation is predominant in the efferent arterioles rather than in the afferent arterioles. Dilatation of the efferent arterioles, even without systemic BP reduction, is thought to decrease transcapillary hydrostatic pressure in the glomerulus and thereby to reduce GFR and proteinuria. Because the protective effects of drugs on the kidney may be related to a reduction of glomerular hypertension, dilazep may play a role in nephroprotection through its effects on the efferent arterioles, as we suggested in our previous studies using efferent arteriole-dilating calcium channel blockers (15, 16) .
The hemodynamic changes induced by dilazep or dipyridamole mimic those induced by intrarenal infusion of adenosine (17) . In addition, treatment with a non-selective antagonist of both A1 and A2 adenosine receptors, 3-isobutyl-1-methyl-xanthine, antagonizes the renal vasodilatation by dilazep (13) . These findings strongly suggest that dilazep dilates the renal vasculature via an adenosine-mediated mechanism.
As previously shown by micropuncture experiments in our (18) and other (19, 20) laboratories, an intraluminal route of application delivers agents through tubular cells into the interstitium surrounding the vascular effector cells in JGA. When dilazep was perfused into the tubular lumen of single nephrons, the macula densa-mediated reduction in EPFR was clearly decreased at the highest concentration, 10 4 mol/l, indicating that TGF response was attenuated at the pharmacological concentration. Because the TGF response involves Furthermore, the reversal of TGF attenuation by co-administration of an A2-specific adenosine receptor antagonist, DMPX, supports the idea that the vasodilatory mechanism of dilazep is mediated by adenosine A2 receptor activation. This is in line with previous reports in which very high concentrations of agonists induced A2 receptor-mediated afferent vasodilatation (19, 21) . Intraluminal perfusion of N-ethyl-carboxamide adenosine (NECA), a preferential A2 receptor agonist, decreased the magnitude of TGF response at the concentration of 10 4 mol/l in perfusate (19) . In the hydronephrotic rat kidney, application of NECA to bath solution dilated both pre-and postglomerular vessels when the concentration reached 10 5 mol/l (21). Thus, our results suggest that intraluminal application of 10 4 mol/l dilazep activates A2 receptors located at the afferent arterioles of JGA, probably via the potentiation of interstitial adenosine, and in turn, attenuates TGF-induced afferent vasoconstriction.
In the present micropuncture experiments, systemic infusion of dilazep at the depressor dose did not affect the reduction in EPFR induced by loop perfusion. The plasma concentration of dilazep in our rats is estimated to be around several hundred nmol/l at 1 h after the start of intravenous highdose infusion with an initial bolus dose (22) . This is comparable with the concentration in human plasma at 1 h after oral administration of 100 mg dilazep. Even if dilazep easily diffuses to the interstitial space or urine because of its relatively low molecular weight (695.6), the concentration around JGA during the systemic infusion should be much less than that which would be achieved during intraluminal application of 4 mol/l dilazep. This seems to be the reason that systemic infusion of dilazep failed to affect TGF response in the present series.
Loop perfusion of DMPX alone did not affect TGF responsiveness. This finding suggests that the TGF mechanism was under little tonic influence of endogenous adenosine on A2 receptors in the current experimental settings. In marked contrast, antagonists selective for adenosine A1 receptors have previously been shown to abolish TGF response either through systemic, luminal, or peritubular application of the drugs (18, 20) ; moreover, A1 agonists have clearly been shown to constrict afferent arterioles isolated from rabbits (23) and to activate TGF response in vivo (19) . When extracellular adenosine is potentiated by dilazep, it might influence afferent arteriolar tone and TGF via A1 receptors in JGA. Our results, however, indicate that the vasoconstriction induced by A1 activation, if any, is not dominant over the vasodilatation by A2 activation during dilazep application, because TGF response was not enhanced but attenuated. Vallon and Osswald (24) reported that in rats treated orally with dipyridamole for three days, TGF activity was enhanced, suggesting that afferent arteriolar tone was increased through vasoconstrictive A1 receptors. The discrepancy between their results and ours might be explained by differences in the experimental protocols, i.e., the acute or chronic treatment, routes of drug administration, and nucleoside transport inhibitors used. In addition, there is a clear difference between the affinities of A1 and A2 receptors to adenosine. While the affinity of the former is so high that the receptor is sensitive to nanomolar concentrations of adenosine, the affinity of the latter is in the micromolar range, and the adenosine concentration in renal interstitial fluids is estimated to be around 0.2 µmol/l (25) . Thus, under the present experimental conditions, which included potentiation of adenosine by dilazep, A1 receptor function may have been masked or dominated by the function of A2 receptors.
In summary, intravenous dilazep (0.3 mg/kg 0.3 mg/kg/h) decreased GFR and systemic BP, but did not affect TGF response in the present study. FF showed a tendency to decrease. Intraluminal dilazep attenuated TGF response at the highest concentration of 10 4 mol/l, and this attenuation was reversed by co-perfusion of DMPX. Luminal perfusion of DM PX alone did not affect TGF response. These results suggest that low-concentration dilazep dilates the postglomerular efferent arterioles but does not influence afferent arteriolar tone. Dilazep at the pharmacological concentration attenuates TGF-induced afferent vasoconstriction. The mechanism of this attenuation could be the activation of vasodilatory A2 receptors in afferent arterioles. Extracellular adenosine augmented by dilazep dilates glomerular vessels at both afferent and efferent sites, probably via the activation of A2 receptors.
